Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning. Welcome to Needham's 21st annual healthcare conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we're proud to have for our next session, Esperion Therapeutics, and we have the company's CEO, Sheldon Koenig, to give us an overview about the company. And then we will jump into Q&A.
So Sheldon, I will hand it over to you to maybe give us a brief overview of Esperion.
Great. Thanks, Serge. And on behalf of Esperion and all the employees here, we really appreciate the opportunity to be here at the Needham conference. I realize it's virtual but I'm positive next year, we will probably be live. I think we said that last year as well. But we really appreciate the opportunity.
Esperion is a company that's really dedicated to cardiovascular medicine. We currently have two products that we are commercializing: NEXLIZET which is bempedoic acid plus ezetimibe; and NEXLETOL which is bempedoic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |